Company Projected Revenue: Chimerix Inc. (CMRX)

Chimerix, Inc. (CMRX) - corporate logo

Chimerix, Inc. (CMRX) specializes in oncology, awaiting the results of Phase 3 trials of ONC201 against glioma. The company's expected sales volume demonstrates a current trend, where the latest value is recorded as 0.00. Growth prospects rely on the imipridone platform and interest from pharma behemoths, while stability is bolstered by the presence of TEMBEXA in the U.S. Strategic National Stockpile for population protection.

Company Expected Sales Volume: Chimerix Inc (CMRX) for 07/04/2022 - 04/26/2025

Summary analytical data breakdowns for Chimerix Inc. (CMRX)

- stock value and consensus price forecast:
Price Chart Chimerix, Inc.|CMRX - Average Forecast Price
- company stock exchange capitalization indicators:
Market Value Chimerix Inc.|CMRX - Total Company Value
- balance sheet equity data:
Net Assets per Single Share Chimerix|CMRX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio chimerix.com|CMRX - Company Balance Sheet Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Chimerix, Inc.|CMRX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Chimerix, Inc|CMRX - Aggregate Debt Obligations|Debt to Book Value Chimerix Inc.|CMRX - Amount of Long-Term Liabilities|Company Short-Term Debts Chimerix|Quick Ratio chimerix.com
- company profitability and valuation multiples indicators:
CMRX - Company Net Income|Expected Profit Chimerix, Inc.|CMRX - Company Value to Net Income|Forward P/E Multiple Chimerix|CMRX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Chimerix Inc.|CMRX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Chimerix|CMRX - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth chimerix.com|CMRX - Net earnings per share growth this year|Earnings growth forecast for next year Chimerix, Inc.
- sales and revenue data:
CMRX - Company Sales Revenue|Projected Sales Volume Chimerix, Inc.|CMRX - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Chimerix Inc.
Fundamental valuation:Chimerix, Inc. CMRX
Product sample of Chimerix Inc

Projected revenue measures the expected cash flow from product sales, determining the fundamental value of the business. For Chimerix, Inc. (CMRX), this calculation is critical due to its dependence on the success of the imidazolinone oncology platform. By analyzing the organization's future sales revenue, an investor assesses the probability of commercializing the key drug. The trend of this metric reflects a transition from binary risk to stable income, allowing for an objective assessment of the issuer's financial stability.

Key competitors

Company Projected Revenue Incyte Corporation (INCY)|HCM - Company Expected Sales Volume|Company Projected Revenue Nuvation Bio NUVB|Day One Biopharmaceuticals, Inc. - Company Projected Revenue|MNPR - Company Projected Revenue|Company Expected Sales Volume Inhibrx Corp|IMAB: Projected Sales Volume|Company Sales Forecast fennecpharma.com FENC|Company Future Sales Volume HRTX|Company Expected Sales Volume Nuvectis Pharma Inc. NVCT|Company Future Sales Volume CHRS (Coherus)|CRBP (Corbus Pharmaceuticals, Inc.) - Company Future Revenue|Cardiff Oncology - Company Future Sales Volume|Company Projected Revenue Volume BYSI (beyondspringpharma.com)|BioAtla Corp - Projected Sales Volume|Company Future Revenue LIXT (Lixte Biotechnology Holdings Inc.)|CTXR: Projected Sales Volume|Company Expected Sales Volume Cellectar Corp (CLRB)|Company Projected Revenue BioLineRx Ltd.|CANF: Company Future Revenue|Projected Sales Volume APRE|Projected Sales Volume kaziatherapeutics.com (KZIA)|Company Projected Revenue Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Company Expected Revenue|CYCC: Company Future Sales Volume|Company Expected Sales Volume G1 Therapeutics, Inc.|KRON: Projected Sales Volume|Company Future Sales Volume Kintara Therapeutics Inc|ONCT (Oncternal) - Projected Sales Volume|PRTG: Company Future Revenue